Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penn Microbiome Therapy for Recurrent C. Difficile Infection
NCT03973697Phase 2Terminated
- Sponsor
- University of Pennsylvania
- Start
- Jan 2020
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Clostridium difficile infection (CDI), sponsored by University of Pennsylvania. Primary endpoint: Number of Subjects With Resolution of Symptoms After Treatment at 8 weeks. Started Jan 2020; status: terminated.
02
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT03973697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03973697.